Sinovac Biotech Ltd. Overview
Pro stress-test →Sinovac Biotech Ltd. is a China-based global biopharmaceutical company focused on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. The company's vaccine portfolio includes CoronaVac® for COVID-19 and Healive® for hepatitis, among other products.
Strategic Profile
Pro stress-test →Sinovac positions itself as a leading provider of biopharmaceutical products in China. The company has faced significant operational challenges, including compliance issues with Nasdaq filing requirements in 2025, triggering a delisting determination in November 2025. However, as of June 2026, the company has regained Nasdaq compliance after filing required annual and interim financial reports.
Competitive Landscape
Pro stress-test →Sinovac competes in the global vaccine market against major manufacturers including state-sponsored Chinese vaccine producers and international pharmaceutical firms. The company's primary market focus is China and emerging markets in Asia, Africa, and Latin America, where it competes on cost-effectiveness and government procurement relationships.
Industry Context
Sinovac Biotech Ltd. operates in Biopharmaceutical Manufacturing and Vaccines.
Key facts
Founded: 1999 · Headquarters: Beijing, China · Employees: 4,281 · Revenue: N/A · Market cap: N/A